老年呼吸道感染患者肺炎支原体抗体检测的调查分析

目的了解老年呼吸道感染患者肺炎支原体（Mycoplasmapneumoniae，MP）感染情况。方法选取广州市红十字会医院2010年1月至2012年9月≥65岁的呼吸道感染患者3765例，男2136例，女1629例，年龄在65～110岁以内，采用间接免疫荧光法（indirectimmunofluorescenceassay，IFA）对其血清中的肺炎支原体抗体（MP—IgM）进行检测。结果3765例老年呼吸道感染患者血清标本中，检出阳性的标本为834例，阳性率为22．15％，其中男性阳性率为21．11％，而女性阳性率为23、51％，不同性别间比较差异无统计学意义（X2=3．080，P〉0．05）。肺炎支原体抗体（MP—IgM）各年龄组问阳性率比较差异无统计学意义（X2=0．090，P〉0．05）。老年呼吸道感染患者肺炎支原体感染阳性率存在季节差异（X2=11．040，P〈o．05），春季、夏季和冬季的老年呼吸道感染患者MP感染率之间比较差异无统计学意义（P〉0．05），而春季、夏季和冬季的老年呼吸道感染患者MP感染率分别与秋季比较差异有统计学意义（P〈0．05）。结论老年呼吸道感染患者有一定的MP感染率，不同性别间差异无统计学意义，感染存在季节的差异性，因老年呼吸道感染患者感染MP合并有基础性疾病时可能会引起严重的损害，故临床应重视老年呼吸道感染患者MP的感染和防治，早发现早治疗；

Investigation on the antibody from respiratory tract of the elderly patients with Mycoplasma pneumoniae

Objective To investigate the respiratory tract infection of the elderly patients with Mycoplasma Pneumoniae （MP）. Methods 3765 patients with respiratory tract infection in Guangzhou Red Cross hospital （ 2136 males, 1629 females ） , aged 65-110, from January 2010 to September 2012. All the patients＇ mycoplasma pneumoniae （MP-lgM） antibody were tested with indirect immunofluorescence assay （IFA）. Results In the 3765 serum specimens from the elderly patients with respiratory infection, the positive specimens were 834 cases and positive rate was 22.15%.There were 2136 male eases （positive rate 21.11%） and 1629 female cases （positive rate 23.51%）.There was no significant difference between them （X 2=3-080, P 〉 0.05）. There was no statistical significant difference in the positive rate between two groups （X 2=0-0900, P 〉 0.05）. There was statistical significant difference in infection positive rate of seasonal difference （X 2= 11.040, P 〈 0.05） . Conclusion There is certain MP infection in the elderly patients with respiratory tract infection.There is no significant difference between males and females. There is difference in onset of seasonal and the elderly patients＇ respiratory tract infection with basic diseases and it may cause serious damage. The clinical treatment should focus on the elderly detection and treatment of the patients with respiratory tract infection and MP infection.